Trial · NCT06907342
Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
NCT06907342, Phase 2, Recruiting, St. Olavs Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1). Trials, record NCT06907342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06907342
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
- NCT number
- NCT06907342
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 148 participants, estimated
- Lead sponsor
- St. Olavs Hospital
- Conditions
- Tumor, Colorectal, Organoids, Tumoroid, Metastatic Colorectal Cancer, Core Needle Biopsy, First-line Treatment
- Interventions
- FOLFOX or FOLFIRI
- First posted
- 2025-04-02
- Last updated
- 2026-07-20
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. | Up to 1 month | Rate of generating valid\* tumouroid response reports per patient included in the trial. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with respect to day 0 or 1. |
| Primary | Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. | Up to 1 month | Rate of generating valid\* tumouroid response reports per patient with obtained tumour sample. \*A valid tumouroid response report for a sample is defined as a fold-change growth in untreated controls of \> 1, registered on day 5, 6, 7 or 8 and normalised with resepect to day 0 or 1. |
| Primary | Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer. | Up to 1 month | What is the time from referral to start of allocated treatment |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Objective Response Rate (ORR) |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Disease Control Rate (DCR) |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Clinical Benefit Rate (CBR), defined as the percentage of patients who had a complete response, partial response, or had stable disease for 6 months or more |
| Secondary | Describe the tumour response to treatment using RECIST v.1.1 | Up to 48 months | Duration of Response (DoR) |
| Secondary | Assess progression free survival | Up to 5 years | Progression Free Survival (PFS), defined as the time from starting first-line treatment to the time of documentation of progressive disease (PD) according to RECIST v.1.1 on active therapy, determined failure of treatment strategy or death |
| Secondary | Assess progression free survival rate | Up to 6 months | Progression Free Survival Rate (PFSR), defined as the ratio of participants with PFS at 6 months |
| Secondary | Assess overall survival | Up to 5 years | Overall Survival |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06907342
GET https://conductscience.org/api/trials/v1/NCT06907342/registered